NasdaqHealth CarePharmaceutical PreparationsZURICH, Switzerland

Veraxa Biotech AG VRXA

Ask your AI

Estimated market cap $156.96M141.41M shares, shares as of Jun 10, 2026CIK 2079109

Insider trades, 12 mo

5 buys · 0 sells

$125.3K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

0.9% of shares · 1 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

What changed in Veraxa Biotech AG's latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

5 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Oct 28, 2026. Insiders have two business days to file.

Recent insider trades

Marc Gruninger Director	Oct 28 Form 4 ↗	Buy	+$9,133 9,133 sh @ $1.00	+15.6%
Marc Gruninger Director	Oct 27 Form 4 ↗	Buy	+$850 867 sh @ $0.98	+13.0%
Christoph Samuel Ziegler Director	Oct 20 Form 4 ↗	Buy	+$32.7K 30,000 sh @ $1.09	+11.8%
Oliver Rolf Baumann Director	Aug 27 Form 4 ↗	Buy	+$75.0K 50,000 sh @ $1.50	-20.7%
Christoph Rudiger Antz Chief Executive Officer, Director	Aug 27 Form 4 ↗	Buy	+$7,650 5,000 sh @ $1.53	-20.7%

All VRXA insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

1.21M shares

5 funds report VRXA. Values checked against market prices.

Funds own 0.3% of shares (Q2 2026)

8 funds hold the stock.

Q3 2026: 0.9% · 5,560 of ~8,900 funds reported so far

Q2 20260.3%
Q3 2026 (so far)0.9%

Q3 2026. 1 new, 1 added to, 2 trimmed, 3 exited since Q2 2026.

Top 13F holders
#
1	Yorkville Advisors Global, LP 13F ↗	1.04M	$1.3M	New
2	Geode Capital Management, LLC 13F ↗	91,528	$114.4K	-23.6%
3	UBS Group AG 13F ↗	72,142	$90.2K	-54.1%
4	Wolverine Asset Management LLC 13F ↗	1,748	$2,185	unchanged
5	JPMorgan Chase & Co 13F ↗	514	$673	+29.8%

Download CSV Every fund that holds VRXA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Veraxa Biotech AG and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Veraxa Biotech AG and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q2 2026	8	—	483,861	$599.6K
Q3 2026	5	-3	1.21M	$1.5M

Each point is a quarter-end, from Q2 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (H9130A103). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes5 in 12 mo 8-K eventsNone in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Veraxa Biotech AG - Post de-SPAC
Address: TALACKER 35, ZURICH, Switzerland 8001
Phone: 41443858450
Fiscal year ends: Dec 31
Filer category: emerging growth company
Incorporated in: Switzerland
Listed as: VRXA (Nasdaq), VRXAW (Nasdaq)
Former names: Veraxa Biotech Holding AG (until 2026)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$1.11−$0.04 (−3.48%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.95 · High $1.26Nov 13, 2026

Aug 13, 2026Low $0.95 · High $1.95Nov 13, 2026

Jun 11, 2026Low $0.95 · High $24.79Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.